LTX-608 by Talphera for Acute Respiratory Distress Syndrome: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LTX-608 overview

Nafamostat mesylate (LTX-608) is under development for the treatment of COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS) and acute pancreatitis. It is administered through intravenous route. It acts by targeting transmembrane protease serine 2 (TMPRSS2).

Talphera overview

Talphera, formerly AcelRx Pharmaceuticals (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo in Europe), is a single sufentanil sublingual tablet for treating of moderate-to-severe acute pain. Its pipeline also includes Zalviso (for US market), a drug and device combination product for the management of moderate to severe acute pain in adults. Talphera developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic drugs. Talphera is headquartered in Hayward, California, the US.

For a complete picture of LTX-608’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.